Who owns X4 Pharmaceuticals, Inc?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of XFOR from SEC Form 13F filings across 88 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 88 institutions disclosed 95.9M shares of X4 Pharmaceuticals, Inc worth $447.9M — about 75.9% of shares outstanding; the largest disclosed holder is MORGAN STANLEY. Source: SEC Form 13F filings, parsed by EvidInvest.
88
13F holders
$447.9M
value, 2026 filers
75.9%
of shares outstanding (95.9M sh)
32
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of XFOR's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 9.5M | $44.2M | 0.0% | 7.5% | -0.1% |
| 2 | FMR LLC | 8.3M | $38.9M | 0.0% | 6.6% | +2.7% |
| 3 | Bain Capital Life Sciences Investors, LLC | 8.0M | $37.2M | 2.2% | 6.3% | 0.0% |
| 4 | PERCEPTIVE ADVISORS LLC | 7.9M | $37.0M | 0.6% | 6.3% | +17.7% |
| 5 | Saturn V Capital Management LP | 7.0M | $32.6M | 4.7% | 5.5% | +8.0% |
| 6 | Empery Asset Management, LP | 6.9M | $32.4M | 37.4% | 5.5% | -22.5% |
| 7 | Deep Track Capital, LP | 5.9M | $27.5M | 0.4% | 4.7% | -7.3% |
| 8 | BlackRock, Inc. | 5.6M | $25.9M | 0.0% | 4.4% | +358.4% |
| 9 | Kalehua Capital Management LLC | 3.7M | $17.4M | 12.5% | 2.9% | 0.0% |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 3.7M | $17.4M | 0.0% | 2.9% | +6.2% |
| 11 | Rosalind Advisors, Inc. | 3.2M | $15.0M | 5.6% | 2.5% | 0.0% |
| 12 | BRAIDWELL LP | 2.9M | $13.6M | 0.5% | 2.3% | -10.7% |
| 13 | Blackstone Inc. | 2.7M | $12.5M | 0.0% | 2.1% | 0.0% |
| 14 | Trails Edge Capital Partners, LP | 2.6M | $12.0M | 1.9% | 2% | 0.0% |
| 15 | Nantahala Capital Management, LLC | 2.4M | $11.4M | 0.4% | 1.9% | 0.0% |
| 16 | BVF INC/IL | 2.2M | $10.4M | 0.3% | 1.8% | 0.0% |
| 17 | GEODE CAPITAL MANAGEMENT, LLC | 2.1M | $9.8M | 0.0% | 1.7% | +123.3% |
| 18 | Venrock Adviser, LLC | 1.9M | $9.0M | 0.3% | 1.5% | +485.2% |
| 19 | SAMSARA BIOCAPITAL, LLC | 1.4M | $6.5M | 0.5% | 1.1% | -23.8% |
| 20 | STATE STREET CORP | 1.3M | $6.1M | 0.0% | 1% | +221.2% |
| 21 | Woodline Partners LP | 1.0M | $4.7M | 0.0% | 0.8% | 0.0% |
| 22 | GOLDMAN SACHS GROUP INC | 916,536 | $4.3M | 0.0% | 0.7% | +3.9% |
| 23 | NORTHERN TRUST CORP | 652,849 | $3.0M | 0.0% | 0.5% | +266.3% |
| 24 | VANGUARD FIDUCIARY TRUST CO | 572,038 | $2.7M | 0.0% | 0.5% | +19.0% |
| 25 | VANGUARD PORTFOLIO MANAGEMENT LLCNEW | 542,128 | $2.5M | 0.0% | 0.4% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.